ArticleScientific reports2018
Quinoxaline protects zebrafish lateral line hair cells from cisplatin and aminoglycosides damage.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Design and Synthesis of New Quinoxaline Analogs to Regenerate Sensory Auditory Hair Cells.Cells · 2025Article
- New application of ombuoside in protecting auditory cells from cisplatin-induced ototoxicity via the apoptosis pathway.Heliyon · 2024Article
- FDA-Approved Tedizolid Phosphate Prevents Cisplatin-Induced Hearing Loss Without Decreasing Its Anti-tumor Effect.Journal of the Association for Research in Otolaryngology : JARO · 2024Article
- Article
- Hair cell toxicology: With the help of a little fish.Frontiers in cell and developmental biology · 2022Review
- Toll-like receptor 4 is activated by platinum and contributes to cisplatin-induced ototoxicity.EMBO reports · 2021Article
- Characterization of quinoxaline derivatives for protection against iatrogenically induced hearing loss.JCI insight · 2021Article
- The Ototoxicity of Antimalarial Drugs-A State of the Art Review.Frontiers in neurology · 2021Review
- Cisplatin-induced hair cell loss in zebrafish neuromasts is accompanied by protein nitration and Lmo4 degradation.Toxicology and applied pharmacology · 2021Article
- Naringin attenuates cisplatin- and aminoglycoside-induced hair cell injury in the zebrafish lateral line via multiple pathways.Journal of cellular and molecular medicine · 2021Article
- BRAF inhibition protects against hearing loss in mice.Science advances · 2020Article
- Fishing for protective compounds.eLife · 2020Article
- Use of zebrafish larvae lateral line to study protection against cisplatin-induced ototoxicity: A scoping review.International journal of immunopathology and pharmacologyArticle
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Hair cell (HC) death is the leading cause of hearing and balance disorders in humans. It can be triggered by multiple insults, including noise, aging, and treatment with certain therapeutic drugs. As society becomes more technologically advanced, the source of noise pollution and the use of drugs with ototoxic side effects are rapidly increasing, posing a threat to our hearing health. Although the underlying mechanism by which ototoxins affect auditory function varies, they share common intracellular byproducts, particularly generation of reactive oxygen species. Here, we described the therapeutic effect of the heterocyclic compound quinoxaline (Qx) against ototoxic insults in zebrafish HCs. Animals incubated with Qx were protected against the deleterious effects of cisplatin and gentamicin, and partially against neomycin. In the presence of Qx, there was a reduction in the number of TUNEL-positive HCs. Since Qx did not block the mechanotransduction channels, based on FM1-43 uptake and microphonic potentials, this implies that Qx's otoprotective effect is at the intracellular level. Together, these results unravel a novel therapeutic role for Qx as an otoprotective drug against the deleterious side effects of cisplatin and aminoglycosides, offering an alternative option for patients treated with these compounds.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.